Genmab (GMAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab A/S, a leading biotechnology firm, announced that Baillie Gifford & Co now holds 4.99% of its shares, signaling a significant investment by the major shareholder. The company, renowned for its innovative antibody therapeutics and ambitious vision to revolutionize treatment for cancer and other serious diseases by 2030, emphasizes its strong international presence and a 25-year legacy of technological advancements in the biotech industry.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.